Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
Go back to Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology| (NASDAQ: PHVS) | Delayed: 34.01 +0.71 (2.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.30 | 52 Week High | $ | |||
| Open | $33.53 | 52 Week Low | $ | |||
| Day High | $34.06 | P/E | N/A | |||
| Day Low | $32.93 | EPS | $ | |||
| Volume | 519,304 | |||||
